![]() ![]() This was a randomized controlled study among one hundred thirty male and female adult Swiss Webster mice in nine different treatment groups namely, P Pellucida as test drug at doses 6.0, 7.5, 9.5, 12.0, 15.0, 19.0, 24.0, 32.0 g/kg body weight, and distilled water as negative control.ġ. To determine the potential systemic toxicity of the acute oral use of Peperomia pellucida freeze-dried aqueous extract powder in mice. It does not store any personal data.Acute oral toxicity of the freeze-dried aqueous extract of Peperomia pellucida (L) HBK ( ulasimang bato) in mice The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". ![]() The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". ![]() ![]() These cookies ensure basic functionalities and security features of the website, anonymously. National Institutes of Health, UP cookies are absolutely essential for the website to function properly. The proponents are currently seeking for pharmaceutical companies who will produce, manufacture and distribute the product. Currently, the product is undergoing clinical trials and is at its pre-commercialization stage (TRL 7). The ulasimang-bato drug formulation already has an existing patent for its tablet form. Also, recurrence of hyperuricemia has not been recorded among patients receiving Ulasimang-bato doses. Results of their studies have shown that ulasimang-bato extract has significantly reduced serum uric acid levels and that the percent reduction is comparable with the effects induced by allopurinol. Based on their studies, optimum dosage is recommended initially at 80 mg/kg/day, and then reduced to 40 mg/kg/day after 2 weeks. The proponents have developed a drug formulation from ulasimang-bato extracts that is targeted to cure hyperuricemia and gout. Peperomia pellucida, locally known as “ulasimang-bato” or “pansit-pansitan”, has long been used in Philippine traditional medicine for its analgesic, anti-inflammatory, and anti-hyperuricemic properties. However, despite its efficacy, cases of hyperuricemia recurrence among allopurinol-treated patients are still reported. Allopurinol, a xanthine oxidase inhibitor, is the standard treatment for gouty arthritis and it acts by lowering uric acid levels in the blood. According to the Philippine Rheumatology Association (PRA), around 1.6M Filipinos are suffering from gout. Gout is the most common type of arthritis among Filipinos. Institute of Herbal Medicine National Institutes of Health, National Integrated Research Program on Medicinal Plants (NIRPROMP), You are here: ULASIMANG BATO: Anti-Inflammatory drug formulation | Philippine Council for Health Research and Development ULASIMANG BATO: Anti-Inflammatory drug formulation Technology Generator ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |